5 completed. 4 Phase 1, 1 Phase 2.
By phase and status
Follow zabedosertib: new trials by email Literature Review of zabedosertib trials Research Report on zabedosertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
Zabedosertib (BAY1834845), Placebo to zabedosertib (BAY1834845) - Atopic Dermatitis | Phase 2 | Completed | 77 | 2022-12-21 | 2025-02-18 |
A Trial to Learn How BAY1834845 and BAY1830839 Affect Inflammation When Taken by Mouth Twice a Day for 7 Days in a Row in Healthy Male Participants
BAY1834845, BAY1830839, Prednisolone - Immune Mediated Inflammatory Diseases | Phase 1 | Completed | 51 | 2021-06-28 | 2022-12-16 |
A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis
BAY1834845, Matching Placebo, Midazolam - Healthy Volunteers, Psoriasis | Phase 1 | Completed | 72 | 2018-04-16 | 2021-02-26 |
Food Effect, Oral & Intravenous Pharmacokinetics and Absolute Bioavailability of BAY1834845 Including Drug-drug Interaction With Methotrexate
BAY1834845, Methotrexate - Inflammation | Phase 1 | Completed | 10 | 2017-08-18 | 2019-07-15 |
First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845
BAY1834845, Placebo - Pelvic Inflammatory Disease | Phase 1 | Completed | 70 | 2017-02-13 | 2019-03-27 |
Conditions studied
Dermatitis, Atopic (1) · Inflammation (1) · Pelvic Inflammatory Disease (1) · Psoriasis (1)
Sponsors
Bayer (5)
Countries
Germany (3) · Netherlands (2) · Czechia (1) · France (1) · Italy (1) · Poland (1) · United Kingdom (1) · United States (1)
Results publications
PMID 40520205, PMID 40906353
NIH funding
2016 (2), 2017 (1)